Research Analysts’ Recent Ratings Updates for Phreesia (PHR)

Several analysts have recently updated their ratings and price targets for Phreesia (NYSE: PHR):

• 10/20/2026 – Phreesia had its “market perform” rating reaffirmed by Citigroup.
• 10/19/2026 – Phreesia was upgraded by Weiss Ratings from “sell (d)” to “sell (d+)”.
• 10/12/2026 – Phreesia had its price target raised by Barclays from $10.00 to $11.00. They now have an “equal weight” rating on the stock.
• 10/10/2026 – Phreesia was upgraded by Wall Street Zen from “hold” to “buy”.
• 9/8/2026 – Phreesia was downgraded by Raymond James Financial from “outperform” to “market perform”.
• 9/5/2026 – Phreesia was downgraded by Wall Street Zen from “buy” to “hold”.
• 9/4/2026 – Phreesia was downgraded by Weiss Ratings from “sell (d+)” to “sell (d)”.
• 9/4/2026 – Phreesia had its price target lowered by DA Davidson from $14.00 to $13.00. They now have a “buy” rating on the stock.
• 9/4/2026 – Phreesia had its price target raised by Robert W. Baird from $10.00 to $11.00. They now have a “neutral” rating on the stock.
• 9/4/2026 – Phreesia had its “market perform” rating reaffirmed by Citigroup.
• 9/3/2026 – Phreesia had its price target raised by Wells Fargo & Company from $9.00 to $10.00. They now have an “equal weight” rating on the stock.
• 9/3/2026 – Phreesia had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $19.00 price target on the stock.
• 9/3/2026 – Phreesia had its “buy” rating reaffirmed by Canaccord Genuity Group. They now have a $16.00 price target on the stock.
• 8/31/2026 – Phreesia had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $14.00 price target on the stock.

Insider Buying and Selling

In other Phreesia news, General Counsel Allison C. Hoffman sold 6,662 shares of Phreesia stock in a transaction on Monday, September 21st. The stock was sold at an average price of $10.08, for a total value of $67,152.96. Following the completion of the transaction, the general counsel directly owned 266,574 shares of the company’s stock, valued at $2,687,065.92. The trade was a 2.44% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 5.20% of the stock is currently owned by company insiders.

Phreesia, Inc is a healthcare technology company that provides a platform for managing administrative and financial interactions between healthcare organizations and their patients. Its software is designed to help medical practices and other care providers streamline registration, intake, payments, communications and related workflows.

The Phreesia platform includes digital patient check-in tools that allow patients to complete forms, update demographic and insurance information, make payments and review relevant educational or administrative content.